PARP inhibitors as P-glyoprotein substrates

Lawlor, Denise, Martin, Patricia, Busschots, Steven, Thery, Julien, O'Leary, John J., Hennessy, Bryan T. and Stordal, Britta K. (2014) PARP inhibitors as P-glyoprotein substrates. Journal of Pharmaceutical Sciences, 103 (6). pp. 1913-1920. ISSN 1520-6017

PDF - First submitted uncorrected version (with author's formatting)
Download (474kB) | Preview


The cytotoxicity of PARP inhibitors olaparib, veliparib, and CEP-8983 were investigated in two P-glycoprotein (P-gp) overexpressing drug-resistant cell models (IGROVCDDP and KB-8-5-11). IGROVCDDP and KB-8-5-11 were both resistant to olaparib and resistance was reversible with the P-gp inhibitors elacridar, zosuquidar, and valspodar. In contrast, the P-gp overexpressing models were not resistant to veliparib or CEP-8983. Olaparib and veliparib did not induce protein expression of P-gp in IGROVCDDP or KB-8-5-11 at doses that successfully inhibit PARP. Olaparib therefore appears to be a P-gp substrate. Veliparib and CEP-8983 do not appear to be substrates. Veliparib and CEP-8983 may therefore be more useful in combined chemotherapy regimens with P-gp substrates and may be active in platinum and taxane-resistant ovarian cancer.

Item Type: Article
Additional Information: Article first published online: 3 APR 2014
Keywords (uncontrolled): olaparib; veliparib; CEP-8983; PARP inhibitor; drug Resistance; cell lines; P-glycoprotein; cancer chemotherapy; toxicity
Research Areas: A. > School of Science and Technology > Natural Sciences > Biomarkers for Cancer group
Item ID: 14450
Notes on copyright: According to SHERPA/RoMEO: author can archive pre-print (ie pre-refereeing)
Useful Links:
Depositing User: Britta Stordal
Date Deposited: 13 Mar 2015 14:20
Last Modified: 04 Apr 2019 06:06

Actions (login required)

Edit Item Edit Item

Full text downloads (NB count will be zero if no full text documents are attached to the record)

Downloads per month over the past year